SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Roche Holdings, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 18,692,766.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 18,692,766.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

18,692,766.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

11

Percent of class represented by amount in row (9)

17.4 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The securities reported in Items 6, 8 and 9 herein consist of (i) 18,055,686 shares of common stock held of record by Roche Holdings, Inc. and (ii) 637,080 shares of common stock held of record by Roche Finance Ltd. The percentage in Item 11 is calculated based upon 107,446,814 shares of the Issuer's common stock outstanding as of July 20, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 24, 2026.

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Roche Finance Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 18,692,766.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 18,692,766.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

18,692,766.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

11

Percent of class represented by amount in row (9)

17.4 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The securities reported in Items 6, 8 and 9 herein consist of (i) 18,055,686 shares of common stock held of record by Roche Holdings, Inc. and (ii) 637,080 shares of common stock held of record by Roche Finance Ltd. The percentage in Item 11 is calculated based upon 107,446,814 shares of the Issuer's common stock outstanding as of July 20, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 24, 2026.

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Roche Holding Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 18,692,766.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 18,692,766.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

18,692,766.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

11

Percent of class represented by amount in row (9)

17.4 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The securities reported in Items 6, 8 and 9 herein consist of (i) 18,055,686 shares of common stock held of record by Roche Holdings, Inc. and (ii) 637,080 shares of common stock held of record by Roche Finance Ltd. The percentage in Item 11 is calculated based upon 107,446,814 shares of the Issuer's common stock outstanding as of July 20, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 24, 2026.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Freenome, Inc.

(b)

Address of issuer's principal executive offices:

Genesis Marina, 3300 Marina Blvd, Brisbane, CA 94005

Item 2.

(a)

Name of person filing:

This Schedule 13G is filed jointly by Roche Holdings, Inc., Roche Finance Ltd and Roche Holding Ltd (collectively, the "Reporting Persons"). Roche Holdings, Inc. is a wholly owned subsidiary of Roche Finance Ltd, which is a wholly owned subsidiary of Roche Holding Ltd. A Joint Filing Agreement is attached as Exhibit 99.1.

(b)

Address or principal business office or, if none, residence:

Roche Holdings, Inc.: 1 DNA Way, Mailstop 49, South San Francisco, California 94080Roche Finance Ltd: Grenzacherstrasse 122, CH 4070 Basel, SwitzerlandRoche Holding Ltd: Grenzacherstrasse 124, CH 4070 Basel, Switzerland

(c)

Citizenship:

Roche Holdings, Inc.: Delaware; Roche Finance Ltd: Switzerland; Roche Holding Ltd: Switzerland

(d)

Title of class of securities:

Common Stock, par value $0.0001 per share

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

See the responses to Item 9 on the attached cover pages. Roche Finance Ltd may be deemed to beneficially own the shares held by Roche Holdings, Inc., its wholly owned subsidiary, and Roche Holding Ltd may be deemed to beneficially own the shares held by both Roche Finance Ltd and Roche Holdings, Inc.

(b)

Percent of class:

See the responses to Item 11 on the attached cover pages.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote:

See the responses to Item 6 on the attached cover pages.

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

See the responses to Item 8 on the attached cover pages.

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Roche Holdings, Inc.

Signature:	/s/ Anjna Mehta
Name/Title:	Anjna Mehta, Authorized Signatory
Date:	09/01/2026

Roche Finance Ltd

Signature:	/s/ Anja Harmeier
Name/Title:	Anja Harmeier, Authorized Signatory
Date:	09/01/2026

Signature:	/s/ Peter Trybus
Name/Title:	Peter Trybus, Authorized Signatory
Date:	09/01/2026

Roche Holding Ltd

Signature:	/s/ Claudia Bockstiegel
Name/Title:	Claudia Bockstiegel, Authorized Signatory
Date:	09/01/2026

Signature:	/s/ Peter Trybus
Name/Title:	Peter Trybus, Authorized Signatory
Date:	09/01/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement